SCHEMBL4944186

SCHEMBL4944186

C=CCn1c(CCC(=O)NCc2ccccc2OC)nnc1SCc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 4/20 0.49
GAA P10253 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP3A4 P08684 1/20 0.49
NPSR1 Q6W5P4 2/20 0.47
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
SLC27A1 Q6PCB7 1/20 0.43
TP53 P04637 2/20 0.43
POLB P06746 3/20 0.42
RECQL P46063 1/20 0.42
CTDSP1 Q9GZU7 1/20 0.42
CYP1A2 P05177 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4944995 0.94 MEN1 (0.47) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4943956 0.94 ALDH1A1 (0.55) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4937961 0.92 ALDH1A1 (0.46) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4944608 0.89 HPGD (0.53) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4944116 0.88 L3MBTL1 (0.47) KMT2AHTTHPGDL3MBTL1TP53
SCHEMBL4947006 0.88 MEN1 (0.49) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4943639 0.88 MEN1 (0.55) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4944560 0.87 HPGD (0.46) MEN1KMT2AALDH1A1GAACYP2D6
SCHEMBL4944931 0.86 POLB (0.51) MEN1KMT2AALDH1A1HPGDL3MBTL1
SCHEMBL4946352 0.85 MAPT (0.51) MEN1KMT2AALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US claimed
EP-1458381-B1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS (AN) 2005-11-30 EP claimed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US claimed
EP-1458381-A1 TRIAZOLES AS OXYTOCIN ANTAGONISTS Applied Research Systems ARS Holding N.V. (AN) 2004-09-22 EP claimed
WO-2003053437-A1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-07-03 WO claimed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187275-A1 Triazoles as oxytocin antagonists OXTR, AVPR2, AVPR1B MEN1 3430/4885KMT2A 4770/4885ALDH1A1 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.